Business Context and Reporting Period
Company: MESA LABORATORIES INC
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: Mesa Laboratories manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, medical sterilization, and pharmaceutical processing. The company operates in two segments: Biological Indicators and Instrumentation Products.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2010 | Six Months Ended Sept 30, 2010 |
|---|---|---|
| Net Sales | $7,754,000 | $15,209,000 |
| Gross Profit | $4,552,000 | $8,933,000 |
| Gross Margin | 58.7% | 58.7% |
| Net Income | $1,429,000 | $2,749,000 |
| Diluted EPS | $0.43 | $0.83 |
| Operating Cash Flow (6mo) | $4,074,000 | |
| Cash and Equivalents (End of Period) | $3,575,000 | |
| Total Debt (Current + Long Term) | $4,271,000 | |
| Current Ratio | 3.0:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 43.4% for the quarter and 46.5% for the six-month period compared to the prior year. This growth is primarily driven by the acquisition of SGM Biotech, Inc. (completed April 27, 2010) and the Torqo product line.
- Profitability: Net income increased 15% for the quarter and 21% for the six-month period. However, gross margins decreased slightly (from 61% to 59% year-to-date) due to a shift in product mix toward Biological Indicators, which have lower margins than Instrumentation products.
- Balance Sheet: Total assets increased from $33.6 million to $43.2 million, driven by the acquisition of SGM Biotech ($11.7M purchase price) and its facility ($2.15M). Cash reserves decreased from $10.5 million to $3.6 million due to acquisition costs and capital expenditures.
- Debt: The company incurred significant new debt to finance acquisitions, totaling $4.27 million in principal obligations as of September 30, 2010, compared to minimal debt in the prior period.
Guidance, Outlook, and Risks
- Outlook: Management expects amortization expenses to rise significantly in fiscal 2011 due to the SGM Biotech acquisition. They anticipate improved margins for Torqo products once manufacturing is transferred to their Lakewood, CO facility by the end of calendar 2010.
- Capital Allocation: The company is minimizing stock buybacks due to lower cash and higher debt positions but continues to pay quarterly dividends ($0.11 per share). Surplus cash flow is being used to retire debt.
- Risks: Key risks include competition in data logging, kidney dialysis, and biological indicator markets; general economic conditions affecting capital spending (specifically noted for Datatrace products); and the impact of increased amortization on future earnings.
- Unusual Items: The company incurred $153,000 in third-party acquisition costs and a one-time $70,000 expense related to a prior period tax deduction misapplication.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost savings associated with moving Torqo manufacturing in-house to confirm margin improvement projections.
- Debt Covenants: Review the restrictive covenants on the new $7 million credit facility ($3M term loan, $4M revolver) to ensure compliance with financial ratios.
- Amortization Impact: Assess the long-term impact of the $2.24 million deferred tax liability and increased intangible asset amortization on future net income.
- Cash Flow Sustainability: Monitor operating cash flow to ensure it remains sufficient to service the new debt load while maintaining dividend payments.
- Product Mix Trends: Track the ratio of Biological Indicator sales to Instrumentation sales to understand the trajectory of gross margins.